Baxter International’s subsidiary, Baxter Healthcare, has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife for up to US$60.8 million, including US$25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones. The transaction reinforces Baxter’s strategy of acquiring products and technologies that both complement and augment the company’s leading portfolio across the hospital, including in the operating room. PerClot has a global commercial presence with sales in more than 35 countries worldwide. It is not currently cleared for sale in the US.
“The addition of PerClot further enhances our ability to optimize patient care by addressing a broad range of intraoperative bleeding with both active and passive haemostatic solutions, helping surgeons to use the right product for the right bleed,” said Wil Boren, president of Baxter’s Advanced Surgery business. “PerClot launches Baxter into the attractive haemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.”
A polysaccharide haemostatic powder can be used as an adjunctive haemostat to facilitate control of bleeding from capillary, venous or arteriolar vessels to address low-grade intraoperative bleeding. PerClot is composed of plant starch that is modified to create an adhesive haemostatic powder. It is used as an adjunctive haemostatic device to control bleeding during multiple open and laparoscopic surgical procedures, including gynaecologic, general, cardiovascular and urology. PerClot rapidly absorbs water from blood to produce a gelled matrix that adheres to and forms a mechanical barrier with the bleeding tissue.
CryoLife recently completed a multicentre, randomised controlled clinical trial of more than 300 patients intended to support an application for FDA clearance. The trial evaluated the safety and efficacy of PerClot in achieving intraoperative haemostasis compared to the control (a similar marketed haemostatic powder).
Seprafilm Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel and bladder.